Floatz logo

Anti-Pr1/Hla-A2 Monoclonal Antibody Hu8F4

Hematopoietic and Lymphoid Cell Neoplasm

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

116 Active assets in the Hematopoietic and Lymphoid Cell Neoplasm cohort.

Asset / SponsorPhaseRating
Fludarabine
National Cancer Institute (NCI)
Phase 3BB
FILGRASTIM
St. Jude Children's Research Hospital
Phase 2BB
Pegloticase
M.D. Anderson Cancer Center
Phase 4BB
Rasburicase
M.D. Anderson Cancer Center
Phase 4BB
Fludarabine
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

Anti-Pr1/Hla-A2 Monoclonal Antibody Hu8F4 is also rated in:

blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
CC
Indicative ·
43 / 100
View asset →
myelodysplastic syndromeDormant
CC
Indicative ·
43 / 100
View asset →
acute myeloid leukemiaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →